Identification
NameAntithymocyte immunoglobulin (rabbit)
Accession NumberDB00098  (BTD00040, BIOD00040)
TypeBiotech
GroupsApproved
Description

Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.

Protein structureDb00098
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
Synonyms
Anti-human thymocyte immunoglobulin, rabbit
Anti-T-lymphocyte immune globulin, rabbit
Anti-thymocyte globulin (rabbit)
Anti-thymocyte globulin rabbit
Antithymocyte immunoglobulin
Rabbit anti-human thymocyte globulin
Rabbit anti-human thymocyte globulin (rATG)
Rabbit anti-human thymocyte immunoglobulin
Rabbit anti-thymocyte immunoglobulin
Rabbit antithymocyte globulin
Rabbit ATG
rATG
Thymoglobulin
Thymoglobuline
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThymoglobulinPowder, for solution25 mgIntravenousSanofi Aventis2003-05-06Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ATG-FreseniusFresenius SE
ATG-Fresenius SFresenius SE
GenzymeNot Available
Thymoglobulin SangStat MedicalNot Available
Brand mixturesNot Available
Categories
UNIID7RD81HE4W
CAS numberNot Available
Pharmacology
Indication

For prevention of renal transplant rejection

Structured Indications
Pharmacodynamics

Antithymocyte Globulin (ATG) is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts.

Mechanism of action

Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.

TargetKindPharmacological actionActionsOrganismUniProt ID
T-cell surface glycoprotein CD1aProteinunknown
inhibitor
HumanP06126 details
Major histocompatibility complex class I-related gene proteinProteinyes
antagonist
HumanQ95460 details
Integrin alpha-LProteinyesNot AvailableHumanP20701 details
T-lymphocyte activation antigen CD86ProteinyesNot AvailableHumanP42081 details
Low affinity immunoglobulin gamma Fc region receptor II-bProteinyesNot AvailableHumanP31994 details
T-cell surface glycoprotein CD4ProteinyesNot AvailableHumanP01730 details
Integrin beta-1ProteinyesNot AvailableHumanP05556 details
Integrin alpha-VProteinyesNot AvailableHumanP06756 details
Integrin beta-3ProteinyesNot AvailableHumanP05106 details
Related Articles
Absorption

T-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.

Route of eliminationNot Available
Half life

2-3 days, may increase after multiple doses administration

ClearanceNot Available
Toxicity

Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Anti-thymocyte Globulin (Rabbit).Approved
FingolimodAnti-thymocyte Globulin (Rabbit) may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anti-thymocyte Globulin (Rabbit).Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).Approved
RindopepimutThe risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Anti-thymocyte Globulin (Rabbit).Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anti-thymocyte Globulin (Rabbit).Approved
SRP 299The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Anti-thymocyte Globulin (Rabbit).Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with TG4010.Investigational
TofacitinibAnti-thymocyte Globulin (Rabbit) may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Anti-thymocyte Globulin (Rabbit).Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Link [Link]
External Links
ATC CodesL04AA04 — Antithymocyte immunoglobulin (rabbit)
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentAcute Kidney Injury (AKI)1
1Active Not RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
1CompletedTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas / Transplantation Infection / Transplantation, Bone Marrow1
1CompletedTreatmentEwings Sarcoma1
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome1
1CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1Not Yet RecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Lymphoma, Hodgkins / Malignancies, Hematologic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non Hodgkin Lymphoma (NHL)1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemia, Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloid Leukemias / Waldenstrom's Macroglobulinemia (WM)1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders1
1RecruitingTreatmentLeukemias1
1RecruitingTreatmentTransplantation, Liver1
1TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
1TerminatedTreatmentAplastic Anaemia (AA)1
1TerminatedTreatmentNeuroblastomas1
1TerminatedTreatmentScleroderma / Sclerosis, Progressive Systemic1
1, 2Active Not RecruitingTreatmentAplastic Anaemia (AA)1
1, 2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2CompletedTreatmentLeukemias / Transplantation, Stem Cell1
1, 2CompletedTreatmentWiskott-Aldrich Syndrome (WAS)1
1, 2Not Yet RecruitingTreatmentAutoimmune Diseases / Diabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Peripheral T-Cell Lymphoma (PTCL) / T-Large Granulocytic Leukemia / T-Lymphoblastic Leukemia/Lymphoma / T-Prolymphocytic Leukemia1
1, 2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2RecruitingTreatmentLeukemias1
1, 2RecruitingTreatmentLeukemias / Malignant Lymphomas1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Lupus Erythematosus1
1, 2Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)1
1, 2Unknown StatusTreatmentEnd Stage Renal Disease (ESRD) / Transplant, Kidney1
1, 2Unknown StatusTreatmentLeukemias1
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAgnogenic Myeloid Metaplasia1
2Active Not RecruitingTreatmentAnemias / Bone Marrow Transplant Failure / Myelodysplastic Syndromes (MDS) / Myeloid Leukemias / Myeloproliferative Disorders / Neural Tube Defects (NTDs)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Active Not RecruitingTreatmentCytopaenia1
2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2Active Not RecruitingTreatmentHemoglobinuria, Paroxysmal Nocturnal (PNH) / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia, Acute Lymphocytic (ALL) / Leukemia, Myeloid, Acute(AML) / Leukemia, Myeloid, Chronic(CML) / Lymphoma, Hodgkins / Lymphoma, Non-Hodgkin (NHL) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Transplantation, Stem Cell1
2Active Not RecruitingTreatmentTransplantation, Kidney1
2CompletedPreventionAcute Renal Allograft Rejection / Cadaveric Donor Renal Transplantation / Induction Therapy1
2CompletedPreventionLiver Dysfunction / Rejection, Transplant / Transplantation, Liver1
2CompletedPreventionPrevention of Kidney Injury Associated With Brain Death1
2CompletedTreatmentALEMTUZUMAB/NATALIZUMAB [VA Drug Interaction] / Evidence of Liver Transplantation / Rejection1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Hematopoietic/Lymphoid Cancer / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia1
2CompletedTreatmentAcquired Aplastic Anemia1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Allogeneic Haematopoietic Stem Cell Transplantation / Leukemias / Malignant Lymphomas1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAplastic Anaemia (AA)2
2CompletedTreatmentAplastic Anaemia (AA) / Myelodysplastic Syndrome1
2CompletedTreatmentBlood Cancers / Leukemias1
2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Leukemias1
2CompletedTreatmentDisorder Related to Renal Transplantation1
2CompletedTreatmentEnd-Stage Renal Disease (ESRD) / Renal Failure1
2CompletedTreatmentGenetic Disorders / Malignancies / Metabolic Diseases1
2CompletedTreatmentHaematological Malignancies2
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentImmunosuppresion / Neutropenias / Pancytopenia / Thrombocytopenias1
2CompletedTreatmentJuvenile Myelomonocytic Leukemia1
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myeloproliferative Disorders / Renal Cancers1
2CompletedTreatmentLeukemias / Transplantation, Stem Cell1
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentMalignant Lymphomas / Transplantation, Bone Marrow1
2CompletedTreatmentMannosidosis / Mucolipidosis Type II (I-cell Disease) / Mucopolysaccharidosis VI / Type 1 Mucopolysaccharidosis1
2CompletedTreatmentRejection, Transplant1
2CompletedTreatmentRejection, Transplant / Transplantation, Renal1
2CompletedTreatmentRenal Failure1
2CompletedTreatmentSickle Cell Disorders1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2RecruitingPreventionAgnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukaemia, Acute / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Small Lymphocytic Lymphoma (SLL)1
2RecruitingPreventionChronic Myeloid Leukemia (CML) / Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Myelodysplastic Syndromes1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemia, Lymphocytic / Leukemias / Lymphoma, Hodgkins / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non Hodgkin Lymphoma (NHL) / Plasma Cell Myeloma1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Congenital Hypoplastic Anemia / Myelodysplastic Syndromes (MDS) / Severe Marrow Failure1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / B-cell Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / T-Cell Non-Hodgkin Lymphoma1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentAplastic Anaemia (AA)1
2RecruitingTreatmentAplastic Anaemia (AA) / Bone Marrow Failure / Immunosuppression / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentAutoimmune Diseases / Autoimmune Disorders1
2RecruitingTreatmentBone Marrow Failure Syndromes / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Transplant, Kidney1
2RecruitingTreatmentEpidermolysis Bullosa1
2RecruitingTreatmentHepatic Failure1
2RecruitingTreatmentLeukemias2
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myeloproliferative Diseases / Plasma Cell Myeloma1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentNon-Malignant1
2RecruitingTreatmentRefractory Non-Hodgkin's lymphoma / Relapsed Non Hodgkin Lymphoma1
2RecruitingTreatmentScleroderma, Systemic1
2RecruitingTreatmentSevere Aplastic Anemia (SAA)2
2RecruitingTreatmentSickle Cell Disorders2
2RecruitingTreatmentTransplant, Kidney1
2SuspendedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Granulocytic Sarcoma / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Myelodysplasia1
2TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCancer, Breast / Cancer, Ovarian1
2TerminatedTreatmentCancers1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia, Lymphoblastic, Acute / Leukemia, Myeloid, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentHaematological Malignancies / Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2TerminatedTreatmentKidney Transplant Recipients1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentMalignancies, Hematologic1
2TerminatedTreatmentMyelodysplastic Syndromes (MDS)1
2TerminatedTreatmentNew-onset Type 1 Diabetes Mellitus1
2TerminatedTreatmentPrimary Renal Allograft Candidate / Transplantation, Kidney1
2TerminatedTreatmentPrimary Simultaneous Kidney and Pancreas Allograft Candidates / Simultaneous Kidney and Pancreas Transplantation1
2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentSickle Cell Disorders1
2TerminatedTreatmentTransplant, Kidney1
2Unknown StatusTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2Unknown StatusTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentAplastic Anaemia (AA)3
2Unknown StatusTreatmentNeoplasms, Hematologic / Tumors, Solid1
2WithdrawnTreatmentCrohn's Disease (CD)1
2, 3Active Not RecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita1
2, 3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2, 3Unknown StatusTreatmentOsteopetrosis1
3Active Not RecruitingTreatmentDisorder Related to Bone Marrow Transplantation / Leukemias / Transplantation Infection1
3CompletedPreventionGraft Versus Host Disease (GVHD)1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Transplantation, Stem Cell1
3CompletedTreatmentChronic Kidney Disease (CKD) / Hyperparathyroidism1
3CompletedTreatmentPancreas-Kidney Transplantation1
3CompletedTreatmentTransplant, Kidney1
3CompletedTreatmentTransplantation, Renal1
3RecruitingTreatmentAcquired Aplastic Anemia1
3Unknown StatusPreventionKidney Failure,Chronic1
3Unknown StatusPreventionLung Transplant1
3Unknown StatusPreventionMalignancies, Hematologic1
3Unknown StatusTreatmentAplastic Anaemia (AA)1
3Unknown StatusTreatmentCardiac Allograft Vasculopathy1
3Unknown StatusTreatmentIschemia-Reperfusion Injury / Transplantation, Kidney1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4Active Not RecruitingTreatmentTransplantation, Renal1
4CompletedNot AvailableEnd-Stage Renal Disease (ESRD) / Living Donors1
4CompletedPreventionDisorder Related to Renal Transplantation1
4CompletedPreventionKidney Transplant Rejection / Transplants and Implants1
4CompletedPreventionTransplant; Failure, Kidney1
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentInfections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentLiving-Donor Kidney Transplants1
4CompletedTreatmentTransplantation, Kidney1
4CompletedTreatmentTransplantation, Renal1
4Not Yet RecruitingTreatmentAplastic Anaemia (AA)1
4Not Yet RecruitingTreatmentLeukemias1
4Not Yet RecruitingTreatmentRenal Failure1
4RecruitingPreventionAcute Graft Versus Host Disease1
4RecruitingTreatmentAcute (Cellular) Renal Allograft Rejection1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentImplant or Graft; Rejection1
4RecruitingTreatmentKidney Transplant Rejection / Kidney Transplant; Complications1
4RecruitingTreatmentThalassemia Major (TM)1
4RecruitingTreatmentThymoglobulin Dose1
4TerminatedPreventionImpaired Renal Function1
4TerminatedTreatmentTransplants and Implants1
4Unknown StatusPreventionDiabetes / Rejection, Transplant1
4Unknown StatusTreatmentImmunosuppression / Liver Diseases / Transplantation, Liver1
4WithdrawnTreatmentReperfusion Injury / Transplantation, Kidney / Transplantation, Renal1
Not AvailableActive Not RecruitingNot AvailablePost-Transplant Infections / Steroid-Free Maintenance Immunosuppression / Thymoglobulin / Transplant Recipient (Kidney)1
Not AvailableActive Not RecruitingNot AvailableRenal Transplant Infection1
Not AvailableActive Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentThyroid Carcinoma1
Not AvailableCompletedNot AvailableAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Graft Versus Host Disease (GVHD)1
Not AvailableCompletedNot AvailableEnd Stage Renal Disease (ESRD)1
Not AvailableCompletedBasic ScienceImmunosuppression / Transplantation, Renal1
Not AvailableCompletedTreatmentAcute Renal Failure (ARF)1
Not AvailableCompletedTreatmentAplastic Anaemia (AA)1
Not AvailableCompletedTreatmentChronic Allograft Nephropathy (CAN) / Transplantation, Kidney1
Not AvailableCompletedTreatmentLeukemias / Malignant Lymphomas1
Not AvailableRecruitingNot AvailableSevere Aplastic Anemia (SAA)1
Not AvailableRecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentAllografts / Transplantation, Lung1
Not AvailableRecruitingTreatmentAplastic Anaemia (AA)1
Not AvailableRecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita1
Not AvailableRecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders1
Not AvailableRecruitingTreatmentHaplo-Cord Transplantation / Malignancies, Hematologic1
Not AvailableSuspendedOtherTransplantation, Kidney1
Not AvailableTerminatedTreatmentTransplantation, Kidney1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous25 mg
Prices
Unit descriptionCostUnit
Thymoglobulin 25 mg vial636.48USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Lipopeptide binding
Specific Function:
Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.
Gene Name:
CD1A
Uniprot ID:
P06126
Uniprot Name:
T-cell surface glycoprotein CD1a
Molecular Weight:
37077.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Peptide antigen binding
Specific Function:
Antigen-presenting molecule specialized in presenting microbial vitamin B metabolites. Involved in the development and expansion of a small population of T-cells expressing an invariant T-cell receptor alpha chain called mucosal-associated invariant T-cells (MAIT). MAIT lymphocytes are preferentially located in the gut lamina propria and therefore may be involved in monitoring commensal flora o...
Gene Name:
MR1
Uniprot ID:
Q95460
Uniprot Name:
Major histocompatibility complex class I-related gene protein
Molecular Weight:
39365.76 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Metal ion binding
Specific Function:
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.
Gene Name:
ITGAL
Uniprot ID:
P20701
Uniprot Name:
Integrin alpha-L
Molecular Weight:
128768.495 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Virus receptor activity
Specific Function:
Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 ...
Gene Name:
CD86
Uniprot ID:
P42081
Uniprot Name:
T-lymphocyte activation antigen CD86
Molecular Weight:
37681.97 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Not Available
Specific Function:
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells ...
Gene Name:
FCGR2B
Uniprot ID:
P31994
Uniprot Name:
Low affinity immunoglobulin gamma Fc region receptor II-b
Molecular Weight:
34043.355 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Zinc ion binding
Specific Function:
Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation. Induces the aggregation of lipid rafts.(Microbial infection) Acts as a receptor for human immunodeficiency virus-1 (PubMed:2214026, PubMed:16331979, PubMed:9641677). Down-regulated by HIV-1 Vpu (PubMed:17346169). Acts as a receptor for Human Herpes virus 7/HHV-7 (PubMed:7909607).
Gene Name:
CD4
Uniprot ID:
P01730
Uniprot Name:
T-cell surface glycoprotein CD4
Molecular Weight:
51110.205 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Virus receptor activity
Specific Function:
Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha...
Gene Name:
ITGB1
Uniprot ID:
P05556
Uniprot Name:
Integrin beta-1
Molecular Weight:
88414.575 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands.(Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for adenovirus type C (PubMed:20615244). Integrin ITGAV:ITGB5 and ITGAV:ITG...
Gene Name:
ITGAV
Uniprot ID:
P06756
Uniprot Name:
Integrin alpha-V
Molecular Weight:
116036.855 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Virus receptor activity
Specific Function:
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/bet...
Gene Name:
ITGB3
Uniprot ID:
P05106
Uniprot Name:
Integrin beta-3
Molecular Weight:
87056.975 Da
References
  1. Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. [PubMed:12586600 ]
Drug created on June 13, 2005 07:24 / Updated on June 14, 2017 14:48